Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ulrike Bockmuehl"'
Autor:
Hande Erdal, Ronald Koschny, Wolfgang Krupp, Manfred Bauer, Ulrike Bockmuehl, Jaromir Sykora, Tom M. Ganten, Jürgen Meixensberger, Wolfgang Stremmel, Henning Walczak, Heidrun Holland, Peter Ahnert
Publikováno v:
Journal of Neuro-Oncology. 97:171-185
TNF-related apoptosis-inducing ligand (TRAIL), a promising novel anti-cancer cytokine of the TNF superfamily, and Bortezomib, the first-in-class clinically used proteasome inhibitor, alone or in combination have been shown to efficiently kill numerou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4e226a79a9781ca31ec71c25b3cfb7
https://doi.org/10.1007/s11060-009-0010-6
https://doi.org/10.1007/s11060-009-0010-6
Autor:
Amir, Minovi, Andreas, Hertel, Ahmet, Ural, Erich, Hofmann, Wolfgang, Draf, Ulrike, Bockmuehl
Publikováno v:
Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat. 17(6)
This study was designed to compare the effectiveness of positron emission tomography (PET) and magnetic resonance imaging (MRI) in the pretherapeutic staging of squamous cell carcinoma (SCC) of the head and neck.The study included 34 consecutive pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe3c0e024b485f5b7f84c48826fe7ba9
https://pubmed.ncbi.nlm.nih.gov/18187997
https://pubmed.ncbi.nlm.nih.gov/18187997
Publikováno v:
Otolaryngology–Head and Neck Surgery. 131
Problem: Besides its intracellular chaperoning function, the major stress-inducible heat shock protein 70 (Hsp70) has been found to play key roles in cancer immunity. Hsp70 was detected on a variety of human tumor cell lines, but not on normal cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bc3c3ed55109f5224186f8807fb6c35
https://doi.org/10.1016/j.otohns.2004.06.317
https://doi.org/10.1016/j.otohns.2004.06.317
Autor:
Ulrike Bockmuehl, Dirk Esser, Sabine Reinisch, Oliver Koelbl, Christian Sittel, Orlando Guntinas-Lichius, Ursula Schroeder, Rudolf Hagen, V Schilling, Martin Goerner, Ulrich Keilholz, C Rudack, Andreas Dietz, Hans Juergen Welkoborsky, Thomas Foerg, Jens Peter Klussmann, Martin Westhofen, Georg Maschmeyer, Thomas Lenarz, Michael Flentje
Publikováno v:
ResearcherID
6016^ Background: The DeLOS-II trial is a German multicenter randomized phase II trial (IIT) investigating IC with or without cetuximab for patients with LHSCC, followed by R assessing FOP. Methods...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68605d3d8090c1bfbf085e9be2505ceb
https://doi.org/10.1200/jco.2014.32.15_suppl.6016
https://doi.org/10.1200/jco.2014.32.15_suppl.6016